Dr. Reddy’s gets FDA approval for branded migraine treatment ZembraceSymTouch

HYDERABAD, India — Dr. Reddy’s Laboratories received approval from the Food and Drug Administration for its ZembraceSymTouch (sumatriptan succinate) injection, the company announced Tuesday. The injection is indicated to treat acute migraines, with or without an aura, in adults. 

 

ZembraceSymTouch marks the first approval Dr. Reddy’s has received from the FDA for a brand-name product in its neurology portfolio. 

 

“Migraine affects millions of patients. Many of these patients have busy lives and quick pain relief is critical to help them manage through their daily routines,” Dr. Redy’s EVP proprietary products Raghav Chari said. “In many cases, migraine episodes are accompanied by severe nausea, making it difficult to swallow and retain pills. ZembraceSymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option."        

 

Each auto-injector contains a 3-mg dose of sumatriptan. The product will be marketed by Promius Pharma in the United States.